Antidepressants Celexa & Lexapro Ineffective for Childhood Depression
On January 24, 2018, Baum Hedlund submitted a 53-page memorandum along with 79 supporting exhibits to the United States Attorney’s Office for the District of Massachusetts detailing how Forest Pharmaceuticals Inc. and Forest Laboratories Inc. (both acquired by Allergan in 2014) deliberately misled the DOJ during its investigation of the drug maker and 2010 settlement of the criminal and civil charges brought against the company.
The government’s investigation of Forest focused on the company’s illegal off-label promotion of a supposedly positive Celexa study (MD-18 or “Wagner study”) and suppression of a negative Celexa study (94404 or the “Lundbeck study,” also known as the “European Study). Documents unearthed during the course of a series of civil lawsuits in Boston have revealed a much deeper deception than the government ever suspected. The government’s case was just the tip of the iceberg.
Forest Pled Guilty to Civil and Criminal Charges For Off-Label Promotion of Celexa and Lexapro For Use in Children and Adolescents
In 2010, Forest entered into a series of settlement agreements with the USAO for the District of Massachusetts. As part of the first agreement, Forest pleaded guilty to one count of obstruction and two counts of distributing a misbranded drug under the Food, Drug, and Cosmetic Act. The third count related to Forest’s promotion of Celexa for use in children and adolescents between 1998 and 2002. Forest paid more than $39 million in criminal fines for Celexa’s off-label promotion.
The second agreement resolved various qui tam False Claims Act lawsuits alleging pharmaceutical fraud through off-label promotion for both Celexa and Lexapro for children and adolescents between 1998 and 2005. Forest paid over $149 million to settle the civil claims.
Lastly, Forest entered into a five-year corporate integrity agreement to address its promotional misconduct.
Each agreement was contingent on the others and required complete honesty from Forest. However, according to unsealed Celexa and Lexapro court docs, the scope and extent of Forest’s fraud was not properly disclosed before the 2010 settlement agreements. Per the documents below, Forest misrepresented material facts underlying the USAO’s investigation.
How Did Forest Mislead the FDA and DOJ About Celexa and Lexapro?
First, A Primer on How Clinical Trials to Test the Efficacy of Medications Work
A drug’s efficacy is determined using double-blind randomized controlled trials (“DBRCTs”). A DBRCT involves the systematic comparison of patients taking a drug and patients taking a placebo. Patients enrolled in the clinical trials are randomly assigned into two groups. One group takes the drug and the other takes a placebo. However, neither the investigators nor the patient know which group each patient is in, i.e., they are “double blind.” Once the study is complete, the benefit observed in the two groups is compared, and if the patients taking the drug meaningfully outperform the patients in the placebo group, the clinical trial is considered positive. If the drug does not outperform placebo, it is called negative.
If either the investigator or the patient is unblinded during the clinical trial, it invalidates the data since there is no way to determine whether the effects observed are caused by the drug as opposed to other factors. Blinding is intended to limit the occurrence of conscious and unconscious bias in the conduct and interpretation of a clinical trial. If either the investigator or the patient knows they are receiving the drug, that knowledge will likely influence their assessment. Numerous studies have confirmed this fact. Blinding is a vital factor in medication research.
Forest Regulatory Affairs Manager: ‘Part of My Job is to Create “Masterful” Euphemisms to Protect Medical and Marketing’
A central feature of the government’s prosecution of Forest involved the promotion and dissemination of Forest’s “positive” Celexa Study MD-18 and the suppression of its negative Celexa Study 94404. What the government did not know is that MD-18 only achieved a positive result through the improper inclusion of nine patients in the study for whom “the blind was unmistakenly [sic] violated” or, as Forest’s medical director put it, who were “automatically unblinded” due to a dispensing error.
Upon learning about the dispensing error mishap, Forest informed the FDA that the unblinded patients would appropriately be excluded from the final analysis. But, when Forest realized the unblinded patients would need to be included to produce a positive result (i.e. show that Celexa was better than a placebo or sugar pill), Forest put the unblinded patients back into the MD-18 analysis and falsely told the FDA the patients were not actually unblinded.
In a draft letter to be sent to the FDA regarding the dispensing error, Amy Rubin, a Forest Regulatory Affairs Manager, characterized the error that caused the patients to become unblinded as only having “the potential to cause patient bias.” Dr. Charles Flicker, the Senior Medical Director overseeing MD-18, did not approve of this language:
“Altho ‘potential to cause bias’ is a masterful stroke of euphemism, I would be a little more up front about the fact that the integrity of the blind was unmistakenly [sic] violated.”
Rubin’s response to Dr. Flicker:
“Thanks for the compliement [sic]. Part of my job is to create ‘masterful’ euphemisms to protect Medical and Marketing.”
“Not only was the disclosure to the FDA dishonest, according to a Forest Regulatory Affairs manager, it was her job to mislead the FDA and protect medical and marketing,” says Baum Hedlund attorney Brent Wisner.
Forest Labs Celexa and Lexapro Court Docs Unsealed
The Exhibits to the January 24, 2018 letter and Memorandum sent by Baum Hedlund to the U.S. Attorney’s Office for the District of Massachusetts (which include court documents obtained in discovery and unsealed over Forest’s objection, as well as deposition testimony of Forest employees and former FDA staffers, etc.) are posted below.
PART I: EXECUTIVE SUMMARY
PART II: CELEXA PEDIATRIC CLINICAL TRIALS
- Celexa Study 94404 Was a Negative Clinical Trial
- Table 1 — Celexa Study 94404 Efficacy Results
- Celexa Study MD-18 Was a Negative Clinical Trial, but Forest Misled the FDA about the Results
Table 2 – Celexa Study MD-18 Efficacy Results
- General Overview of MD-18 Study
- At the Beginning of the Trial, a Packaging Error Caused Nine Patients, and their Investigators, to Become Unblinded
- Celexa Study Dispensing Diagram
- Forest Knowingly Misled the FDA about the Nature of the Unblinding by Using, As Forest Regulatory Affairs Manager Put It, “Masterful Euphemisms” to “Protect Medical and Marketing”
- Despite Misrepresenting the Unblinding to the FDA, Forest Promised to Exclude the Data from the Patients from Its Primary Efficacy Analysis
- Forest Reneged on its Promise to Exclude the Unblinded Patients from the Primary Efficacy Results and, Again, Misrepresented the Unblinding in MD-18’s Final Study Report
- The FDA Never Fully Considered the Unblinding Issue and a Reasonable Regulator at the FDA Could Review this New Information and Conclude Study MD-18 Was Negative
- Forest Also Misled the FDA about the Results of the Secondary Endpoints
- Table 3 — Comparison of MD-18 Study Report & Dr. Heart Medical Review
PART III: FOREST USED FALSE RESULTS FROM MD-18 TO PROMOTE PEDIATRIC USE OF CELEXA AND LEXAPRO
PART IV: THE LEXAPRO PEDIATRIC TRIALS
- Lexapro Study MD-15 Was a Negative Clinical Trial
- Table 4 – Lexapro Study MD-15 Efficacy Results
- Lexapro Study MD-32 Was a “Positive” Clinical Trial for Adolescents, but Did Not Show a Meaningful Difference between Lexapro and Placebo
PART V: FOREST LEVERAGED THE FALSE RESULTS OF MD-18 TO OBTAIN AN ADOLESCENT INDICATION FOR LEXAPRO
PART VI: FOREST USED THE FALSE ASSERTION THAT MD-18 WAS POSITIVE AND THE FDA’s APPROVAL FOR LEXAPRO TO NEGOTIATE REDUCED PENALTIES IN USAO CASE
Pilliod et al. v, Monsanto Co. $2 Billion
Dewayne “Lee” Johnson v. Monsanto Co. $289.2 Million
Pharmaceutical Settlement $105 Million
Hardeman v. Monsanto Co. $80 Million
Paxil Pediatric Class Action $63 Million
Third-Party Payer Class Action $40 Million
Defective Drug Class Action $28 Million
Whistleblower Settlement $18 Million
$18 million settlement for Boeing government overcharging on aircraft maintenance
A Major US Plane Crash $17.5 Million
Commercial Truck Accident $15 Million
$15 million settlement for a person gravely injured by a major truck company
“The Baum, Hedlund firm has some of the top legal minds in the country; they are driven, determined, trustworthy, ethical and passionate.”- From Best Lawyers® Best Law Firms
Top Legal Minds in the Country- From Best Lawyers® Best Law Firms
I Can’t Imagine a Better Law Firm- Best Law Firms Survey
Diligent & Professional Representation- W.T.
Our Best Interest Was Always Number One on Your List- G.C. & C.C
We Have Never Met a More Wonderful Group of People- The B. Family